Medicare moves to expand coverage for weight-loss drugs Wegovy, Zepbound

WASHINGTON — The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the blockbuster weight-loss drugs Wegovy and Zepbound, the White House announced Tuesday. 

Medicare currently covers the medications made by Novo Nordisk and Eli Lilly to treat diabetes and heart disease, but not for obesity alone because it’s prohibited by law from doing so. Given the price tag, a bill in Congress to extend coverage has stalled for years. Advocates for greater coverage have long argued that Medicare had the power to change coverage policy on its own.

Read the rest…